EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight

Areej Turkistani, Haydar M Al-Kuraishy, Ali I Al-Gareeb, Athanasios Alexiou, Marios Papadakis, Mostafa M Bahaa iD, Salah Al-Windy, Gaber El-Saber Batiha

Immunity, Inflammation and Disease · 2024-08 · 12 (8)

DOI: 10.1002/iid3.1346 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 02.08.2024. Verfasst von Areej Turkistani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Medicine, Taif University, Taif, Saudi Arabia. Hauptthemen laut MEDLINE: Metformin, Atherosclerosis, Hypoglycemic Agents, Kruppel-Like Transcription Factors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Witten/Herdecke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atherosclerosis (AS) is a progressive disease that interferes with blood flow, leading to cardiovascular complications such as hypertension, ischemic heart disease, ischemic stroke, and vascular ischemia. The progression of AS is correlated with inflammation, oxidative stress, and endothelial dysfunction. Various signaling pathways, like nuclear erythroid‐related factor 2 (Nrf2) and Kruppel‐like factor 2 (KLF2), are involved in the pathogenesis of AS. Nrf2 and KLF2 have anti‐inflammatory and antioxidant properties. Thus, activation of these pathways may reduce the development of AS. Metformin, an insulin‐sensitizing drug used in the management of type 2 diabetes mellitus (T2DM), increases the expression of Nrf2 and KLF2. AS is a common long‐term macrovascular complication of T2DM. Thus, metformin, through its pleiotropic anti‐inflammatory effect, may attenuate the development and progression of AS.

Aims

Therefore, this review aims to investigate the possible role of metformin in AS concerning its effect on Nrf2 and KLF2 and inhibition of reactive oxygen species (ROS) formation. In addition to its antidiabetic effect, metformin can reduce cardiovascular morbidities and mortalities compared to other antidiabetic agents, even with similar blood glucose control by the Nrf2/KLF2 pathway activation.

Conclusion

In conclusion, metformin is an effective therapeutic strategy against the development and progression of AS, mainly through activation of the KLF2/Nrf2 axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminAtherosclerosisHypoglycemic AgentsKruppel-Like Transcription FactorsNF-E2-Related Factor 2Diabetes Mellitus, Type 2HumansAnimalsOxidative StressSignal TransductionReactive Oxygen Species

Stichwörter der Autor:innen

Kruppel like factor 2atherosclerosismetforminnuclear erythroid related factor 2

Substanzen

MetforminHypoglycemic AgentsKruppel-Like Transcription FactorsNF-E2-Related Factor 2KLF2 protein, humanReactive Oxygen SpeciesNFE2L2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Medicine, Taif University, Taif, Saudi Arabia.
  • Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
  • Department of Clinical Pharmacology and Medicine, Jabir ibn Hayyan Medical University, Kufa, Iraq.
  • Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.
  • AFNP Med, Wien, Austria.
  • Department of Research & Development, Funogen, Athens, Greece.

ORCID-Profile: Mostafa M Bahaa

Förderung

  • Universität Witten/Herdecke

Zitieren

APA

Turkistani, A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A., Papadakis, M., Bahaa, M. M., Al-Windy, S., & Batiha, G. E. (2024). Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight. Immunity, Inflammation and Disease, 12(8). https://doi.org/10.1002/iid3.1346

Vancouver

Turkistani A, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Bahaa MM, et al. Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight. Immunity, Inflammation and Disease. 2024;12(8). doi:10.1002/iid3.1346

BibTeX
@article{Turkistani2024,
  author = {Turkistani, Areej and Al-Kuraishy, Haydar M and Al-Gareeb, Ali I and Alexiou, Athanasios and Papadakis, Marios and Bahaa, Mostafa M and Al-Windy, Salah and Batiha, Gaber El-Saber},
  title = {Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  volume = {12},
  number = {8},
  doi = {10.1002/iid3.1346}
}
Kostenlos starten →